Shares of Izotropic Rise1 as Prototype of New 3D Breast Imaging Device Is Unveiled
Editorial | Feb 23, 2023 | Tech
Little-known Izotropic Corporation (OTCQB:IZOZF | CSE:IZOOTCQB:IZOZF | CSE:IZO) could be the investment opportunity of 2023.
Savvy investors know a quick way to make money is by investing early in a new medical technology with the potential to impact the lives of millions.
For example, early investors in Transmedics Group (TMDX), which makes devices to aid organ transplants, saw their shares skyrocket in 2022 – despite the overall sell-off in the stock market.
The shares rose in price from $142 a share in January 2022 to over $613 a share by the end of the year – a gain of 328%4 in just 12 months.
Now something similar could be happening with a small, little-known medical device company called Izotropic Corporation (OTCQB:IZOZF | CSE:IZOOTCQB:IZOZF | CSE:IZO).
Fully Engineered Device Now Revealed
After years of testing and development, the company has unveiled its long-awaited, pre-commercial prototype of a revolutionary new 3D breast imaging technology, dubbed IzoView.
This completed prototype comes after four successive, fully-functioning breast CT prototypes were developed at UC Davis Medical Center as an academic pursuit. Commercialization efforts began when Izotropic was granted the exclusive global licensing rights to the technology from The Regents of The University of California.
The device could be a game-changer for women’s health — potentially improving and even saving the lives of thousands of women every year.
The breakthrough breast imaging platform could allow radiologists to view high-resolution 3D images comparable to MRI as part of the initial, low-cost, low-radiation dose routine breast cancer imaging in the future – as many as 40 million per year – and not have to order and then wait for expensive follow-up tests.
The “buzz” surrounding this new technology is real. The new device will be featured on an upcoming segment of the national TV show “Advancements with Ted Danson” via Amazon Prime Video and Bloomberg TV.5
Shares Jump 112% in Last 6 Months in 2022
Based on reports of early design proposals alone, shares of Izotropic Corporation (OTCQB:IZOZF | CSE:IZOOTCQB:IZOZF | CSE:IZO) soared 112 percent6 in the second half of 2022.
The reason for the interest is obvious. According to the American Cancer Society, approximately 1 in 8 women (13%) will be diagnosed with invasive breast cancer at some point in their lifetime.
In raw numbers, that means every year in the United States 297,0007 women get the bad news – and 43,0008 die from the disease.
Plus, IzoView revolutionizes how women have diagnostic procedures performed.
A New, More Comfortable, More Private Method for Breast Imaging
A traditional diagnostic x-ray mammogram can require up to 12 individual “views,” with each view taking up to 20 seconds of painful, sometimes agonizing compression to complete.
Between each view, a technician has to handle the patient’s breast as it is repositioned in the compression plates. As a result, an x-ray mammogram can take between 20 and 45 minutes to complete.
What’s more, the images produced are often not ideal. Anatomical structures can be distorted, and there is no differentiation between macro-and micro-calcifications in the breast tissue – crucial for identifying potential tumors.
IzoView is radically different. Instead of women standing in front of an old-fashioned x-ray machine that requires vice-like breast compression between metal plates, the Izotropic device lets women lie on a comfortable tabletop and place their own breast in an opening in the table.
Beneath the bed-like table, an advanced computed tomography (CT) camera moves around the breast in a 360-degree circle, taking approximately 500 images in just 10 seconds.
Proprietary AI computer software then takes these 500 raw image slices of the non-compressed breast and reconstructs the slices into high-resolution 3D images of the entire breast.
The pre-commercialized prototypes created at UC Davis have been used in extensive academic clinical trials with more than 600 patients. UC Davis is currently in the data analysis stage of a clinical trial comparing breast CT to MRI, with the results to be released soon.
The Advantages of High-Resolution 3D Imaging Over Traditional Mammograms
The greater comfort and privacy are of paramount importance, but they are merely two of the many benefits of IzoView CT imaging for breast diagnostics.
First, Izotropic Corporation’s (OTCQB:IZOZF | CSE:IZOOTCQB:IZOZF | CSE:IZO) breakthrough 3D imaging system eliminates compression altogether.
Natural breast orientation is preserved with the patient placing her own breast in the imaging cup, so there is no embarrassing handling by a technician. This also ensures that there is excellent visualization with contrast.
Further, the imaging procedure is over in a flash. The system takes 500 high-resolution images in approximately 10 seconds with about the same level of radiation from just two traditional mammogram views.
What’s more, Izotropic is developing new image reconstruction software utilizing the latest machine learning algorithms to deliver both high resolution and low noise images at low radiation dose levels.
Aside from improved detection capabilities, IzoView is a potential solution for more precise margin analysis (viewing edges of a tumor), better “lesion characterization” (the detailed description of an abnormality), and higher spatial resolution, allowing radiologists to better differentiate internal breast structures.
Women and Doctors Eager for the “Next Stage” in Breast Health
As a result, the “buzz” is substantial around this potentially breakthrough technology in women’s health – and it’s not just investors that are so excited about the IzoView 3D imaging platform.
Patients are already asking when the technology will be available and for a good reason!
The IzoView 3D imaging platform is…
- A solution for Patients: Patients enjoy a pain-free, comfortable, and more private procedure that is over in seconds rather than in 20 to 45 minutes.
- A solution for Doctors: Doctors benefit because the 3D visualization and contrast expand use cases and can aid diagnosis
- A solution for Hospitals & Clinics: The 3D imaging system can improve patient throughput and attract more customers
- A solution for Insurers: Could lower costs by lowering the number of false positives that lead to unnecessary (and costly) biopsies
Half of Women Will Likely Get a Devastating False Breast Cancer Diagnosis
False positives are common in traditional breast imaging: False positives are when old-fashioned mammograms reveal abnormalities in the breast tissue that later tests and biopsies reveal are actually benign and not cancerous tumors.
About 50 percent of women who get annual mammograms over a ten-year period will have a false-positive finding at least once.
The problem is, these false positives cause tremendous stress and worry for thousands of women, not to mention unnecessary biopsy procedures – and the follow-up imaging exams and biopsies can cost tens of thousands of dollars per patient.
The Market for Breast Imaging to Soar to $5.4 Billion by 2025
Thus, the market for Izotropic Corporation’s (OTCQB:IZOZF | CSE:IZOOTCQB:IZOZF | CSE:IZO) new breast imaging platform is potentially enormous. It’s estimated that the market for breast imaging technology will grow from $3.7 billion in 2020 to $5.4 billion by 2025.9
What’s more, 40 million women receive a mammogram each year in the United States.
Of these, about 10 percent – or 4 million — are called back for expensive follow-up tests, such as diagnostic mammograms, tomosynthesis, ultrasound, MRI, and biopsies.10
An advanced breast imaging technology like the one Izotropic has designed and is submitting to the FDA could potentially save America’s struggling health care systems billions of dollars – and would be extremely attractive for hospitals and health care managers.
A recent study found that the cost of follow-up imaging and diagnostic procedures after initial mammograms was more than $8 billion11 annually, just in the United States alone.
U.S. Government Funding and Patents
In addition to investor funds, approximately $20 million in U.S. government grants has been invested to develop this ground-breaking, potentially life-saving technology at the UC Davis Medical Center in Sacramento, California. Izotropic is primed to advance important initiatives, with news flow expected to be strong in the months ahead.
The fully-functioning prototype technology has been upgraded and reengineered by Izotropic’s engineers and technical team to deliver IzoView: a state-of-the-art breast imaging device for the future to be used on the masses. The experience and importance for patients, operators, insurance providers, and customers have been further studied by Izotropic to yield what the Company believes is a design and functionality that, once approved for sale, will drive demand, acceptance, and market uptake.
The researchers developing the IzoView platform have 10 unique U.S. patents and patent-pending applications, including for using breast CT to measure breast density, to perform robotic guided biopsies, to protect its unique radiation self-shielding design, and to incorporate a 3D-beam modulation filter that shapes IzoView’s x-ray beam to match the shape of the patient’s breast and further reducing the radiation dose.
The patent for biopsies is particularly noteworthy. 71 percent of the 1.6 million breast biopsies performed in the U.S. are found to be negative at the cost of $2.2 billion.14
Looking to the Future
Izotropic is setting up its long-term platform strategy to increase customer appeal with more add-ons.
After market entrance as a diagnostic device, the Company plans to offer solutions across the gamut of breast health care, including screening and diagnosis in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstruction surgery.
A CEO and Scientific Advisory Team Like No Other
In addition, the management of Izotropic Corporation (OTCQB:IZOZF | CSE:IZOOTCQB:IZOZF | CSE:IZO) is fully committed to bringing this disruptive imaging technology to market.
Dr. John McGraw, MSc, Ph.D, CEO, Director
- Senior VP of Business Development & Strategy, CML Healthcare (TSX: CLC) Canada’s largest provider of medical imaging services acquired by Lifelabs for C$1.2B.
- VP Operations for Novadaq Technologies Inc. (NASDAQ: NCVQ), a medical device imaging company acquired by Styker Corporation for USD $701M.
Dr. John Boone, Principal Founder of Breast CT Technology & Director
- Editor-In-Chief of Medical Physics, the official journal of the American Association of Physicists in Medicine (AAPM).
- Commissioner of the International Commission of Radiation Units & Measurements (ICRU)
- Co-author of “The Essential Physics of Medical Imaging,” the leading textbook for radiology residents
Dr. Younes Achkire, Ph.D., Chief Operating Officer
- Founder, CTO/VP of Engineering & Operations at ZAP Surgical Systems, Inc.
- VP of Engineering Equipment Technology & Operations at Solyndra
- Engineering & Design Consultant, Varian Medical Systems
A Low-Priced Stock with Blockbuster Potential
As a publicly-traded company only founded in 2016, shares of Izotropic Corporation (OTCQB:IZOZF | CSE:IZOOTCQB:IZOZF | CSE:IZO) are currently selling for less than a dollar – but likely not for long.
The stock gained 112%12 from June 2022 to mid-January 2023, and is expected to garner a lot more attention throughout 2023.
Only about 51.813 million shares are outstanding. That means the current market capitalization is tiny, especially given the “disruptive” nature of Izotropic’s technology and the fact that it’s the only publicly traded Company developing this kind of platform to address the growing problem of breast cancer.
Getting Ready to Launch
The Company is currently in the process of calibrating IzoView’s imaging processes – and is preparing for a clinical study to collect data that it will use for an FDA application for approval of an indication for use as a diagnostic device.
When FDA approval has been awarded, the Company will ramp up marketing of its revolutionary IzoView platform to the thousands of hospitals and clinics throughout the United States that perform breast imaging.
The Company is already participating in the FDA’s Center for Devices & Radiological Health Payor Communication Task Force program and can use historical trial data in discussions with insurance payers to demonstrate patient benefits for insurance coverage of the Company’s new IzoView platform.
Hundreds of Millions of Women Could Soon Demand This Technology
Women worldwide have already begun hearing about a brand-new, easy, and compression-free way to do breast imaging – lying comfortably for a few seconds on an imaging table rather than standing in front of an x-ray machine while their breasts are compressed between metal plates.
As word continues to get out, the demand for this disruptive new technology could be intense – and then all bets are off for shares in Izotropic Corporation (OTCQB:IZOZF | CSE:IZOOTCQB:IZOZF | CSE:IZO).
The time to investigate this Company is now, before it submits this major breakthrough in breast imaging technology to the FDA.
1 From $0.2590 at the close on June 28, 2022, to $0.54 per share at the close on Jan 13, 2023, per https://finance.yahoo.com/quote/IZOZF/history?p=IZOZF. That was a gain of 112.3% in just over 6 months, per https://percentagecalculator.net/
2 Closed at $14.42 per share on January 27, 2022, per https://finance.yahoo.com/quote/TMDX/history
3 Closed at $61.72 on December 30, 2022, per https://finance.yahoo.com/quote/TMDX/history
4 https://percentagecalculator.net/
5 https://izocorp.com/news-releases/izotropics-izoview-breast-ct-device-to-be-featured-on-advancements-tv-show-in-usa/
6 From $0.2590 at the close on June 28, 2022, to $0.54 per share at the close on Jan 13, 2023, per https://finance.yahoo.com/quote/IZOZF/history?p=IZOZF. That was a gain of 112.3% in just over 6 months, per https://percentagecalculator.net/
7 https://www.cancer.org/content/dam/CRC/PDF/Public/8577.00.pdf
8 https://www.cancer.org/content/dam/CRC/PDF/Public/8577.00.pdf
9 https://www.marketsandmarkets.com/PressReleases/breast-imaging-technologies.asp
10 Corporate Presentation, September 2020, p. 10.
11 Slide 7, https://izocorp.com/site/assets/files/5623/final_jan_2023_izo_investor_presentation.pdf
12 From $0.2590 at the close on June 28, 2022 to $0.54 per share at the close on Jan 13, 2023, per https://finance.yahoo.com/quote/IZOZF/history?p=IZOZF.That was a gain of 112.3% in just over 6 months, per https://percentagecalculator.net/
13 https://izocorp.com/site/assets/files/5623/final_jan_2023_izo_investor_presentation.pdf
14 Corporate Presentation, September 2020, p. 10.
IMPORTANT NOTICE AND DISCLAIMER
This article is a paid advertisement. Think Ink Marketing and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by profiled companies or third parties to organize marketing campaigns, which include the creation and dissemination of these types of communications. In this case, in an effort to enhance public awareness of Izotropic Corporation (“IZO”) and its securities, IZO has provided the Publisher with a budget of approximately $10,000.00 USD to cover the costs associated with creating and distribution of this communication. The Publisher may retain any excess sums after expenses as its compensation. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by IZO ) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP.
The Publisher does not own any shares of any profiled company IZO and has no information concerning share ownership by others of in the profiled company IZO . The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
FORWARD LOOKING STATEMENTS.
This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to IZO industry; (b) market opportunity; (c) IZO business plans and strategies; (d) services that IZO intends to offer; (e) IZO milestone projections and targets; (f) IZO expectations regarding receipt of approval for regulatory applications; (g) IZO intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) IZO expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute IZO business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) IZO ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) IZO ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) IZO ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of IZO to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) IZO operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact IZO business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing IZO business operations (e) IZO may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
INDEMNIFICATION/RELEASE OF LIABILITY.
By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY.
Think Ink Marketing is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
IMPORTANT NOTICE AND DISCLAIMER
This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Website Host has not been compensated by any of the profiled companies. The Website Host’s compensation for articles appearing on this website is as follows:
- The Website Host has been paid approximately $500 per week while the advertisement campaign is active by Think Ink Marketing as compensation to host the article profiling Izotropic Corporation.
SHARE OWNERSHIP
The Website Host does not own any shares of any profiled Izotropic Corporation. and has no information concerning share ownership by others of any profiled companies and The Website Host cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
NO SECURITIES OFFERED
The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of any Izotropic Corporation. or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the Izotropic Corporation.. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled Izotropic Corporation.’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Website Host, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
LINKS TO THIRD PARTY WEBSITES
This website enables users to link to external websites not under the control of The Website Host. The Website Host has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Website Host expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.
INTELLECTUAL PROPERTY
The Market Tactic is the Website Host’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Website Host is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Website Host to any rights in any third-party trademarks.
FORWARD LOOKING INFORMATION
This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect expectations regarding Izotropic Corporation. future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Izotropic Corporation. industry; (b) market opportunity; (c) Izotropic Corporation. business plans and strategies; (d) services that Izotropic Corporation. intends to offer; (e) Izotropic Corporation. milestone projections and targets; (f) Izotropic Corporation. expectations regarding receipt of approval for regulatory applications; (g) Izotropic Corporation. intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Izotropic Corporation. expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Izotropic Corporation. business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Izotropic Corporation. ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Izotropic Corporation. ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) Izotropic Corporation. ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Izotropic Corporation. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Izotropic Corporation. operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact Izotropic Corporation. business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Izotropic Corporation. business operations (e) Izotropic Corporation. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
HISTORICAL INFORMATION
Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Izotropic Corporation. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Izotropic Corporation. or such entities and are not necessarily indicative of future performance of Izotropic Corporation. or such entities.